EGFR and non-small cell lung carcinoma: Evans evaluated the PD-L1 status with 22C3 assay amongst 10,005 NSCLC patients in England and identified that patients who were EGFR-wild type or ALK-positive were more likely to present both positive and strong positive PD-L1 [21].